間褐色脂肪組織のチェレンコフ発光イメージング

Executive Industry Relevance

Cerenkov luminescence imaging (CLI) with F-18 FDG provides a cost-effective, accessible alternative to PET for monitoring brown adipose tissue (BAT) activation in preclinical models. This approach supports early-stage metabolic target validation by enabling in vivo visualization of thermogenic activity in small animals, facilitating hypothesis testing and mechanistic de-risking in obesity and diabetes research. CLI’s rapid, inexpensive workflow allows iterative screening of pharmacological interventions affecting energy expenditure, improving predictive confidence in lead identification.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of BAT activation mechanisms via norepinephrine stimulation and cold exposure, supporting functional validation of thermogenic targets.
• Operational Value: Provides quantitative luminescence readouts to assess target engagement and pathway modulation in vivo.
• Predictive Value: Facilitates early triage of compounds affecting energy expenditure by correlating CLI signal with metabolic outcomes.

Screening & Assay Development

• Scientific Value: Establishes a reproducible optical imaging platform for longitudinal BAT monitoring, reducing reliance on terminal assays.
• Operational Value: Standardizes signal acquisition and spectral unmixing procedures to minimize variability across experimental groups.
• Scalability: Supports multi-timepoint imaging (30, 60, 120 minutes post-injection) for kinetic analysis of tracer uptake and clearance.

Translational & Preclinical Research

• Translational Continuity: Links rodent BAT activation data to human-relevant metabolic endpoints, supporting extrapolation to clinical obesity and diabetes indications.
• Mechanistic De-risking: Uses 3D tomographic reconstruction to confirm signal origin in interscapular BAT, reducing false positives from superficial tissue accumulation.
• Risk-Adjusted Advancement: Enables longitudinal tracking of BAT depression under prolonged anesthesia, informing safety assessments of CNS-active compounds.

Pipeline & Workflow Integration

CLI fits within the discovery continuum from target validation through preclinical efficacy testing, offering a non-invasive, repeatable readout for metabolic pathway modulation. Its integration enables seamless transition from in vitro screening to in vivo confirmation of target engagement in adipose tissue.

• Discovery Biology: Supports hypothesis-driven interrogation of adrenergic and thermal regulation of BAT, clarifying mechanism of action for sympathomimetic compounds.
• Screening: Delivers standardized, quantitative luminescence outputs suitable for hit-to-lead progression in metabolic screening cascades.
• Analytics: Generates spectral unmixing and 3D reconstruction data that allow precise signal attribution and longitudinal comparison across treatment groups.
• Translational Research: Connects acute BAT activation readouts to chronic energy expenditure models, supporting dose-response and durability assessments.
• Enterprise Reuse: Requires only basic optical imaging infrastructure, enabling broad deployment across discovery and preclinical sites without cyclotron access.

Operational & Enterprise Impact

• Scientific Value: Increases target validation confidence by providing direct, visual evidence of BAT activation in intact physiological context.
• Operational Value: Eliminates need for PET/CT infrastructure, reducing per-sample cost and turnaround time for metabolic imaging.
• Strategic Value: Accelerates go/no-go decisions in metabolic programs by delivering early, mechanistic insights into energy expenditure effects.
• Portfolio Impact: Improves risk-adjusted resource allocation by identifying compounds with genuine thermogenic potential prior to costly GLP studies.

Implementation Considerations

• Requires expertise in handling radioactive isotopes (F-18 FDG) and small animal imaging protocols.
• Dependent on access to a low-light optical imaging system with multispectral filter capabilities and spectral unmixing software.
• Necessitates standardization of animal preparation, injection timing, and environmental conditions (e.g., temperature, anesthesia depth) to ensure reproducibility.
• Limited to superficial or moderately deep tissues due to optical scattering; signal validation via 3D coregistration is essential for deeper targets.
• Signal quantification depends on proper background subtraction and region-of-interest placement to distinguish specific BAT signal from nonspecific luminescence.

Biopharma FAQs